AlzChem Group Past Earnings Performance
Past criteria checks 6/6
AlzChem Group has been growing earnings at an average annual rate of 19.4%, while the Chemicals industry saw earnings growing at 9.6% annually. Revenues have been growing at an average rate of 9.8% per year. AlzChem Group's return on equity is 26.1%, and it has net margins of 8.9%.
Key information
19.4%
Earnings growth rate
19.4%
EPS growth rate
Chemicals Industry Growth | 12.4% |
Revenue growth rate | 9.8% |
Return on equity | 26.1% |
Net Margin | 8.9% |
Next Earnings Update | 28 Feb 2025 |
Recent past performance updates
Recent updates
AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point
Nov 14AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story
Oct 27When Should You Buy AlzChem Group AG (ETR:ACT)?
Oct 18AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Sep 07A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Jun 04AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
May 08Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 26Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
Mar 29The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
Mar 07Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching
Nov 01Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?
Oct 12AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
May 06AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05
Apr 05AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
Mar 04AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year
Apr 24AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00
Mar 29AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00
Feb 27AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?
Jun 10At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?
Apr 07AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?
Mar 23AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price
Mar 10Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 24Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)
Feb 11Revenue & Expenses Breakdown
How AlzChem Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 564 | 50 | 165 | 0 |
30 Jun 24 | 555 | 46 | 161 | 0 |
31 Mar 24 | 546 | 39 | 155 | 0 |
31 Dec 23 | 546 | 35 | 149 | 0 |
30 Sep 23 | 533 | 30 | 143 | 0 |
30 Jun 23 | 554 | 28 | 140 | 0 |
31 Mar 23 | 570 | 30 | 140 | 0 |
31 Dec 22 | 550 | 30 | 139 | 0 |
30 Sep 22 | 534 | 29 | 136 | 0 |
30 Jun 22 | 487 | 28 | 135 | 0 |
31 Mar 22 | 454 | 27 | 134 | 0 |
31 Dec 21 | 429 | 28 | 133 | 0 |
30 Sep 21 | 420 | 27 | 135 | 0 |
30 Jun 21 | 406 | 26 | 133 | 0 |
31 Mar 21 | 397 | 23 | 129 | 0 |
31 Dec 20 | 386 | 20 | 129 | 0 |
30 Sep 20 | 370 | 16 | 127 | 0 |
30 Jun 20 | 389 | 17 | 127 | 0 |
31 Mar 20 | 387 | 17 | 127 | 0 |
31 Dec 19 | 385 | 18 | 125 | 0 |
30 Sep 19 | 389 | 19 | 124 | 0 |
30 Jun 19 | 380 | 18 | 122 | 0 |
31 Mar 19 | 380 | 20 | 120 | 0 |
31 Dec 18 | 383 | 23 | 118 | 0 |
30 Sep 18 | 380 | 22 | 114 | 0 |
30 Jun 18 | 398 | 32 | 123 | 0 |
31 Mar 18 | 364 | 21 | 115 | 0 |
31 Dec 17 | 361 | 20 | 114 | 0 |
30 Sep 17 | 356 | 22 | 115 | 0 |
31 Dec 16 | 333 | 15 | 111 | 0 |
30 Sep 16 | 331 | 12 | 108 | 0 |
31 Dec 15 | 329 | 15 | 106 | 0 |
31 Dec 14 | 298 | 14 | 98 | 0 |
Quality Earnings: ACT has high quality earnings.
Growing Profit Margin: ACT's current net profit margins (8.9%) are higher than last year (5.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACT's earnings have grown by 19.4% per year over the past 5 years.
Accelerating Growth: ACT's earnings growth over the past year (65.3%) exceeds its 5-year average (19.4% per year).
Earnings vs Industry: ACT earnings growth over the past year (65.3%) exceeded the Chemicals industry 7.2%.
Return on Equity
High ROE: ACT's Return on Equity (26.1%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/01 00:05 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AlzChem Group AG is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Laura Lopez Pineda | Baader Helvea Equity Research |
Konstantin Wiechert | Baader Helvea Equity Research |
Knut Woller | Baader Helvea Equity Research |